Ontario Teachers Pension Plan Board Makes New $394,000 Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

Ontario Teachers Pension Plan Board bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 33,284 shares of the company's stock, valued at approximately $394,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its holdings in Roivant Sciences by 0.3% during the 4th quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares during the last quarter. Invesco Ltd. lifted its holdings in Roivant Sciences by 49.7% during the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after buying an additional 3,159,603 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Roivant Sciences by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 7,771,831 shares of the company's stock worth $91,968,000 after buying an additional 26,727 shares during the last quarter. Finally, Norges Bank purchased a new stake in Roivant Sciences during the 4th quarter worth about $52,443,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Trading Up 3.0 %

Shares of Roivant Sciences stock traded up $0.31 on Wednesday, hitting $10.73. The stock had a trading volume of 2,607,832 shares, compared to its average volume of 5,406,968. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The stock has a market cap of $7.66 billion, a price-to-earnings ratio of -71.53 and a beta of 1.25. The company's 50 day moving average price is $10.32 and its 200 day moving average price is $11.16.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In related news, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Eric Venker sold 218,041 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at $9,345,374.98. This trade represents a 19.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock worth $14,922,538 in the last quarter. Company insiders own 7.90% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ROIV. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Monday. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.